Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.76 per share a year ago.
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PEN stays on investors' radars due to its strong Thrombectomy business and international growth plans.
Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Shares of Penumbra Inc PEN recovered slightly in early trading on Tuesday, after a week of correction.
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.